VIVUS Newswire

Comprehensive Real-Time News Feed for VIVUS.

Results 1 - 20 of 209 in VIVUS

  1. Orexigen: Contrave Sales On The Cusp Of Anti-Obesity Leadership - Do Not Celebrate YetRead the original story w/Photo

    19 hrs ago | Seeking Alpha

    ... scripts. In contrast, Arena's (NASDAQ: ARNA ) Belviq was down 3.02% to just above 14,200 scripts, and Qsymia from Vivus (NASDAQ: VVUS ) was down 1% to just below 11,700. Essentially, Contrave is on the cusp of passing Belviq and has managed to ...

    Comment?

  2. Orexigen: Contrave Sales Flattening - Europe Needed To Spur NumbersRead the original story w/Photo

    Wednesday May 20 | Seeking Alpha

    ... prior. In contrast, Belviq from Arena (NASDAQ: ARNA ) saw sales dip 1% on just under 14,700 bottles, and Qsymia from Vivus (NASDAQ: VVUS ) saw sales climb 1.72% to just under 11,900. For the first time in quite a while, Contrave was not the weekly ...

    Comment?

  3. Vivus: Qsymia Sales Win The Week, But Is It Enough?Read the original story w/Photo

    Wednesday May 20 | Seeking Alpha

    Vivus investors had a bit of something to smile about when the sales figures in the anti-obesity sector came out last week, but a smile and true equity appreciation are two distinct and different things. Qsymia sales were up 1.72% week over week to a level just below 11,900.

    Comment?

  4. VIVUS Announces Scientific PresentationsRead the original story w/Photo

    Thursday May 14 | AndhraNews

    VIVUS, Inc. , a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity , sleep apnea, diabetes and sexual health, today announced the following scientific presentations: Date/Time Poster Presentation Date : Friday, May 15, 2015, 9:45am - 11:00am and 12:30pm - 2:00pm CT Session Location: Exhibit Hall, Hall B, Third Floor of the Music City Convention Center.

    Comment?

  5. Arena Pharmaceuticals Takes The Early Lead In The International Obesity RaceRead the original story w/Photo

    Apr 3, 2015 | Seeking Alpha

    ... the U.S. launches of Belviq (12,535 after 6 weeks), Orexigen's (NASDAQ: OREX ) Contrave (12,120 after 7 weeks), or Vivus's (NASDAQ: VVUS ) Qsymia (12,281 after 10 weeks). The debut is even more impressive given the other blogger's dim view of the ...

    Comment?

  6. Vivus' Stendra To Get A Re-LaunchRead the original story w/Photo

    Monday May 11 | Seeking Alpha

    Vivus investors got a bit of good news today when Endo International announced its quarterly results . Endo recently merged with Auxilium , the company that had the rights to Stendra in the United States.

    Comment?

  7. Enteromedics Working On Launch; Reports Loss, Approaches $1 Per Share AgainRead the original story w/Photo

    Monday May 11 | Seeking Alpha

    ... like a "no-brainer". It is the same type of appeal that saw investors flock to Arena Pharmaceuticals (NASDAQ: ARNA ), Vivus (NASDAQ: VVUS ) and to a lesser extent, Orexigen (NASDAQ: OREX ). Investors in Arena and Vivus that played the initial ...

    Comment?

  8. Many Pin Their Hopes On Vivus's Chances In Latin AmericaRead the original story w/Photo

    Apr 3, 2015 | Seeking Alpha

    On May 5, Vivus, Inc. reported financial results for the first quarter that ended March 31, 2015. As predicted , Vivus surpassed revenue estimates , and even beat earnings by $0.07.

    Comment?

  9. Orexigen Therapeutics' Contrave Margins Shrink, Still Needs Progress In EuropeRead the original story w/Photo

    Apr 3, 2015 | Seeking Alpha

    ... anti-obesity market was flat (+1.4% WOW), with minimal gains by Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq and Vivus' (NASDAQ: VVUS ) Qsymia. Workforce reductions by Vivus and Arena's partner, Eisai (OTCPK: ESALY ), seem to be taking their toll ...

    Comment?

  10. VIVUS Stock Rating Upgraded by ZacksRead the original story w/Photo

    Saturday May 9 | AmericanBankingNews.com

    ... Zacks 's price target points to a potential upside of 11.34% from the company's current price. Zacks' analyst wrote, "VIVUS' first quarter results were better-than-expected with the company reporting a narrower-than-expected loss as well as ...

    Comment?

  11. Vivus - Qsymia Script Sales Flat Again - Should Vivus Concentrate On Stendra?Read the original story w/Photo

    Friday May 8 | Seeking Alpha

    Vivus announced financial results for the first quarter this week and saw Qsymia sales during the past week post a very modest rise, but are essentially flat. Qsymia was the first of the newer anti-obesity drugs to launch, but has seen itself passed by the second to launch Belviq from Arena and now the third to launch Contrave from Orexigen.

    Comment?

  12. Orexigen - Contrave Scripts Grow, But Reality On Revenue May Shock YouRead the original story w/Photo

    Friday May 8 | Seeking Alpha

    ... see revenue of about $4.8 million in Q1 on the sale of about 174,000 scripts. This would be about $27.50 per bottle. Vivus (NASDAQ: VVUS ) has no partner on Qsymia and saw $12.6 million in revenue on 136,000 scripts. The average revenue per bottle ...

    Comment?

  13. Orexigen Posts Loss - Revenue Will Be The StoryRead the original story w/Photo

    Friday May 8 | Seeking Alpha

    ... Europe would give the company a substantial foothold in countries where Arena's (NASDAQ: ARNA ) Belviq and Qsymia from Vivus (NASDAQ: VVUS ) are not approved. Overall Orexigen saw a loss of $0.14 cents per share and reported a big improvement from ...

    Comment?

  14. VIVUS (VVUS) Seth H. Z. Fischer on Q1 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    Tuesday May 5 | Seeking Alpha

    Good day, ladies and gentlemen, and welcome to the VIVUS 2015 First Quarter Financial Results Teleconference. At this time, all participants are in a listen-only mode.

    Comment?

  15. VIVUS (VVUS) Set to Announce Quarterly Earnings on TuesdayRead the original story w/Photo

    Sunday May 3 | AmericanBankingNews.com

    VIVUS will announce its Q115 earnings results on Tuesday, May 5th. Analysts expect the company to announce earnings of per share and revenue of $21.80 million for the quarter.

    Comment?

  16. Why Vivus Is Undervalued At Anything Under $10 Per ShareRead the original story w/Photo

    Thursday Apr 30 | Seeking Alpha

    Vivus has the most effective anti-obesity drug on the market and is about to benefit from synergistic government policy. I generally avoid longing stocks, favoring call options instead.

    Comment?

  17. VIVUS Announces Date Of First Quarter 2015 Update And Financial Results Conference CallRead the original story

    Wednesday Apr 29 | BioSpace

    VIVUS, Inc. today announced that it will provide an update and report financial results for the first quarter ended March 31, 2015 after the NASDAQ Market closes on Tuesday, May 5, 2015. The company will conduct a conference call and an audio webcast at 4:30 pm EDT the same day.

    Comment?

  18. Vivus Inks Deal To Make Qsymia More Affordable, But Will It Spur Sales?Read the original story w/Photo

    Wednesday Apr 29 | Seeking Alpha

    ... Sam's Club will certainly help maintain the sales pace, but whether or not it can drive sales is another matter. Many Vivus investors seem to be looking for any glimmer of positives from this company. News like this deal may fuel the fires of hope, ...

    Comment?

  19. Court Report - April 2015 #4Read the original story w/Photo

    Monday Apr 27 | JD Supra

    ... and sale of its Bionect Gel (hyaluronic acid gel, used for various skin diseases and disorders). View the complaint Vivus, Inc. v. Teva Pharmaceuticals USA, Inc. et el. 2:15-cv-02693; filed April 15, 2015 in the District Court of New Jersey ...

    Comment?

  20. Vivus- Qsymia Sales Continue To Stumble Along- Equity Does The SameRead the original story w/Photo

    Monday Apr 27 | Seeking Alpha

    Vivus saw one of its best weekly gains of the year in Qsymia sales this past week, but with this drug is seems to be more of a stumbling forward than putting together consistent growth. The movement in the stock is much the same as the movement in Qsymia sales.

    Comment?